Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background and Aims: Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases. Approach and Results: We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH. Conclusion: Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“The presence of lipid droplets containing TGs in hepatocytes is a hallmark of NAFLD, and multiple genes involved in lipogenesis, fatty acid uptake and oxidation contribute to this phenomenon (23).”
BackgroundAMP-activated protein kinase: an energy sensor that regulates all aspects of cell function
Hardie, D. G. (2011) · Genes & Development · doi:10.1101/gad.17420111 · Cited by 1,638
Trefts, E., Gannon, M., & Wasserman, D. H. (2017) · Current Biology · doi:10.1016/j.cub.2017.09.019 · Cited by 1,452
AMPK signalling in health and disease
Carling, D. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.01.005 · Cited by 797 · cited 1×
“AMPK has been reported to be an anti-inflammatory protein that is involved in the regulation of energy homeostasis (43), and cordycepin has been revealed to activate AMPK by binding with the α1 and γ1 subunits near the autoinhibitory domain of AMPK (44).”
BackgroundLytic cell death in metabolic liver disease
Gautheron, J., Gores, G. J., & Rodrigues, C. M. P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.001 · Cited by 225 · cited 1×
“Lipotoxicity eventually leads to hepatocyte injury or even death (24); thus, serum ALT and AST levels were measured.”
BackgroundReport on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Rinella, M. E., Tacke, F., Sanyal, A. J., & Anstee, Q. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.019 · Cited by 209
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
Self-citationMetabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Li, S., Chen, F., Zou, Y., Ning, L., Zhang, G., Zhang, S., & Yao, Q. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-4809 · Cited by 10
He, R., Du, Y., Jiang, W., & Zhou, W. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118299
Metadata
- Authors
- Lan, T., Yu, Y., Zhang, J., Li, H., Weng, Q., Jiang, S., Tian, S., Xu, T., Hu, S., Yang, G., Zhang, Y., Wang, W., Wang, L., Zhu, Q., Rong, X., & Guo, J.
- Venue
- Hepatology
- Published
- 2021-08
- Volume
- 74
- Issue
- 2
- Pages
- 686-703
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3126632176
- Cited by
- 187
- References
- 7
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway. https://app.cochat.ai/papers/10.1002/hep.31749
- The paper
- Lan, T., Yu, Y., Zhang, J., Li, H., Weng, Q., Jiang, S., Tian, S., Xu, T., Hu, S., Yang, G., Zhang, Y., Wang, W., Wang, L., Zhu, Q., Rong, X., & Guo, J. (2021). Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway. Hepatology. https://doi.org/10.1002/hep.31749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.